Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
microRNA-373-3p mimic
- Development stage
- Preclinical
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Intratumoral
01
Overview
microRNA-373-3p mimic is a synthetic, chemically modified double-stranded RNA molecule designed to emulate the biological activity of the endogenous mature microRNA-373-3p. It functions by incorporating into the RNA-induced silencing complex (RISC) and binding to the 3' untranslated region (UTR) of specific target messenger RNAs (mRNAs), leading to their degradation or translational inhibition. In prostate cancer research, miR-373-3p has been shown to target the Transforming growth factor-beta receptor type 2 (TGFBR2), thereby modulating the TGF-β/SMAD signaling pathway. This mimic is primarily used in preclinical research to investigate the tumor-suppressive roles of miR-373-3p in various cancers, where it has been observed to inhibit cell proliferation, migration, and invasion.
- Other names
- miR-373-3p mimicmiR373-3p mimicmiR 373-3p mimichsa-microRNA-373-3p mimichsa-microRNA373-3p mimichsa-microRNA 373-3p mimic
02
Targets
TGFBR2 (TGF-β receptor type 2)CD44 (CD44 antigen)
Beyond the preview
Go deeper on microRNA-373-3p mimic.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on microRNA-373-3p mimic.